116 related articles for article (PubMed ID: 3917530)
1. Factor VIII.
McCarthy NJ
Med J Aust; 1985 Jan; 142(1):74-5. PubMed ID: 3917530
[No Abstract] [Full Text] [Related]
2. Report of the subcommittee on human factor VIII and factor IX preparations.
Brinkhous KM
Thromb Diath Haemorrh Suppl; 1968; 35():233. PubMed ID: 5761064
[No Abstract] [Full Text] [Related]
3. Recommendations of the subcommittee on human factor VIII (AHF) and factor IX (PTC) preparations.
Wagner RH
Thromb Diath Haemorrh Suppl; 1968; 35():235-7. PubMed ID: 5761065
[No Abstract] [Full Text] [Related]
4. Safer factor VIII and IX.
Lancet; 1986 Aug; 2(8501):255-6. PubMed ID: 2874281
[No Abstract] [Full Text] [Related]
5. Utilization of previously treated patients (PTPs), noninfected patients (NIPs), and previously untreated patients (PUPs) in the evaluation of new factor VIII and factor IX concentrates. Recommendation of the Scientific Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis.
White GC; DiMichele D; Mertens K; Negrier C; Peake IR; Prowse C; Schwaab R; Yoshioka A; Ingerslev J
Thromb Haemost; 1999 Mar; 81(3):462. PubMed ID: 10102478
[No Abstract] [Full Text] [Related]
6. Laboratory testing and standardisation.
Barrowcliffe TW
Haemophilia; 2013 Nov; 19(6):799-804. PubMed ID: 24165153
[No Abstract] [Full Text] [Related]
7. Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.
McGrath KM; Thomas KB; Herrington RW; Turner PJ; Taylor L; Ekert H; Schiff P; Gust ID
Med J Aust; 1985 Jul; 143(1):11-3. PubMed ID: 2989666
[TBL] [Abstract][Full Text] [Related]
8. [An unified method of one-stage quantitative analysis of factors VIII and IX. I. (Results of the studies of the working group of the All-Union Problem-Solving Commission on "Pathology of hemostasis")].
Barkagan ZS
Gematol Transfuziol; 1991 Apr; 36(4):33-5. PubMed ID: 1906034
[No Abstract] [Full Text] [Related]
9. Clinical studies with treated clotting factor concentrates.
Colombo M; Mannucci PM
Dev Biol Stand; 1987; 67():333-6. PubMed ID: 3038639
[TBL] [Abstract][Full Text] [Related]
10. Virus safety of pasteurized factor VIII and factor IX concentrates: study in virgin patients.
Heimburger N; Karges HE; Weidmann E
Dev Biol Stand; 1987; 67():303-10. PubMed ID: 3038638
[TBL] [Abstract][Full Text] [Related]
11. Why prescribe highly purified factor VIII and IX concentrates?
Berntorp E
Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
[TBL] [Abstract][Full Text] [Related]
12. Concentrated therapeutic fractions of coagulation factors prepared in Europe.
Soulier JP
Thromb Diath Haemorrh Suppl; 1967; 26():391-400. PubMed ID: 6064869
[No Abstract] [Full Text] [Related]
13. Concentrate safety and efficacy.
Kasper CK
Haemophilia; 2002 May; 8(3):161-5. PubMed ID: 12010404
[TBL] [Abstract][Full Text] [Related]
14. Effect of using safer blood products on prevalence of HIV infection in haemophilic Canadians. Canadian Hemophilia Clinic Directors Group.
BMJ; 1993 Jan; 306(6873):306-7. PubMed ID: 8461649
[No Abstract] [Full Text] [Related]
15. Factor VIII and IX inhibitors after exposure to heat-treated concentrates.
Pasi KJ; Hamon MD; Perry DJ; Hill FG
Lancet; 1987 Mar; 1(8534):689. PubMed ID: 2882112
[No Abstract] [Full Text] [Related]
16. Detection of factor VIII and IX inhibitors after first exposure to heat-treated concentrates.
Hasegawa DK; Edson JR
Lancet; 1987 Feb; 1(8530):449. PubMed ID: 2880242
[No Abstract] [Full Text] [Related]
17. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators.
Dodt J; Hubbard AR; Wicks SJ; Gray E; Neugebauer B; Charton E; Silvester G
Haemophilia; 2015 Jul; 21(4):543-9. PubMed ID: 25623631
[TBL] [Abstract][Full Text] [Related]
18. Transmission of hepatitis B by dry heat treated factor VIII and IX concentrates.
Lush CJ; Chapman CS; Mitchell VE; Martin C
Br J Haematol; 1988 Jul; 69(3):421. PubMed ID: 3136793
[No Abstract] [Full Text] [Related]
19. Evaluation of human viral disease transmission through plasma products.
Heldebrant CM; Friedman AE; Fedor EJ
Dev Biol Stand; 1987; 67():319-22. PubMed ID: 2440744
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis G virus in clotting factor concentrates.
Alonso-Rubiano E; Gerber M; Friedman P; Hodges S; Leissinger C
Haemophilia; 2003 Jan; 9(1):110-5. PubMed ID: 12558787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
